RSK2, a serine/threonine kinase downstream signaling mediator in the RAS/MEK/ERK pathway, has been identified as driving invasiveness/migration in glioma and other cancers [52,53,54]; hence, it is a favorable downstream target and a potential biomarker of the FAK+MEK inhibitor combination. This evidence concerns the gene MAP2K7 and central nervous system cancer.